GREEN BAY, Wis., Sep 15, 2005 (BUSINESS WIRE) -- Enzymatic Therapy, Inc. announced that it has completed its corporate restructuring as of today, September 15, 2005. The Company merged all of the operations of its wholly owned subsidiaries and created a holding company structure - ETI Holdings, Inc. As a result, the Company's structure better aligns its legal entities with its operating divisions and will provide the flexibility to help the Company achieve its growth objectives through potential acquisitions, continued new product development and improved product positioning.
The ETI Holdings Inc. Enzymatic Therapy Brand is the fastest growing of the top brands in Health Food Store formats, as measured by SPINS data services. The company recently acquired US distribution rights to Remifemin(TM) and Alluna(TM), two brands that are sold throughout the United States to leading retailers. Driven by its mission to provide consumers with "What Better Feels Like! (TM)" the company continues to develop innovative, science-based natural medicines, nutritional supplements, vitamins and herbal extracts. The company's therapeutic products are extensively researched, lab-tested for purity, potency and bioavailability and manufactured in the company's organically certified, FDA registered drug facility. To find out more about Enzymatic Therapy, please visit www.enzy.com
Statements made in this release that are not historical, including statements made regarding costs, estimates of growth, and sales of Enzymatic Therapy products, may be considered forward looking statements within the Private Securities Litigation Reform Act of 1995. ETI Holdings, Inc., cautions that readers should not place undue reliance on any forward-looking statements, which speak only as of the date made. ETI advises that various risks and uncertainties could affect its financial performance, and could cause ETI Holdings, Inc.'s. actual results for future periods to differ materially from those anticipated or projected.